These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 35544598)

  • 1. Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia.
    Laukkanen S; Veloso A; Yan C; Oksa L; Alpert EJ; Do D; Hyvärinen N; McCarthy K; Adhikari A; Yang Q; Iyer S; Garcia SP; Pello A; Ruokoranta T; Moisio S; Adhikari S; Yoder JA; Gallagher K; Whelton L; Allen JR; Jin AH; Loontiens S; Heinäniemi M; Kelliher M; Heckman CA; Lohi O; Langenau DM
    Blood; 2022 Oct; 140(17):1891-1906. PubMed ID: 35544598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical evaluation of proteolytic targeting of LCK as a therapeutic approach in T cell acute lymphoblastic leukemia.
    Hu J; Jarusiewicz J; Du G; Nishiguchi G; Yoshimura S; Panetta JC; Li Z; Min J; Yang L; Chepyala D; Actis M; Reyes N; Smart B; Pui CH; Teachey DT; Rankovic Z; Yang JJ
    Sci Transl Med; 2022 Aug; 14(659):eabo5228. PubMed ID: 36001679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia.
    Harr MW; Caimi PF; McColl KS; Zhong F; Patel SN; Barr PM; Distelhorst CW
    Cell Death Differ; 2010 Sep; 17(9):1381-91. PubMed ID: 20300113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of an Orally Bioavailable LCK PROTAC Degrader as a Potential Therapeutic Approach to T-Cell Acute Lymphoblastic Leukemia.
    Jarusiewicz JA; Yoshimura S; Actis M; Li Y; Fu X; Yang L; Narina S; Pruett-Miller SM; Zhou S; Wang X; High AA; Nishiguchi G; Yang JJ; Rankovic Z
    J Med Chem; 2024 Jul; 67(14):11868-11884. PubMed ID: 38973320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting eIF4F translation complex sensitizes B-ALL cells to tyrosine kinase inhibition.
    Vo TT; Herzog LO; Buono R; Lee JS; Mallya S; Duong MR; Thao J; Gotesman M; Fruman DA
    Sci Rep; 2021 Nov; 11(1):21689. PubMed ID: 34737376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-targeting of Akt and Myc inhibits viability of lymphoma cells from Lck-Dlx5 mice.
    Tan Y; Sementino E; Pei J; Kadariya Y; Ito TK; Testa JR
    Cancer Biol Ther; 2015; 16(4):580-8. PubMed ID: 25793663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL.
    Leonard JT; Kosaka Y; Malla P; LaTocha D; Lamble A; Hayes-Lattin B; Byrd K; Druker BJ; Tyner JW; Chang BH; Lind E
    Blood; 2021 Feb; 137(7):939-944. PubMed ID: 32898857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre T-cell receptor alpha (pTalpha) expression patterns and functional analysis in human T-cell lymphoblastic leukemia.
    Ivanyi P; Morgan M; Piao W; Ukena SN; Steube K; Ganser A; Franzke A
    Cell Oncol; 2010; 32(1-2):101-8. PubMed ID: 20208138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph
    Vo TT; Lee JS; Nguyen D; Lui B; Pandori W; Khaw A; Mallya S; Lu M; Müschen M; Konopleva M; Fruman DA
    Mol Cancer Ther; 2017 Sep; 16(9):1942-1953. PubMed ID: 28566433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II-like murine trial identifies synergy between dexamethasone and dasatinib in T-cell acute lymphoblastic leukemia.
    Shi Y; Beckett MC; Blair HJ; Tirtakusuma R; Nakjang S; Enshaei A; Halsey C; Vormoor J; Heidenreich O; Krippner-Heidenreich A; van Delft FW
    Haematologica; 2021 Apr; 106(4):1056-1066. PubMed ID: 32139432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategies.
    Cordo' V; Meijer MT; Hagelaar R; de Goeij-de Haas RR; Poort VM; Henneman AA; Piersma SR; Pham TV; Oshima K; Ferrando AA; Zaman GJR; Jimenez CR; Meijerink JPP
    Nat Commun; 2022 Feb; 13(1):1048. PubMed ID: 35217681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia.
    Serafin V; Capuzzo G; Milani G; Minuzzo SA; Pinazza M; Bortolozzi R; Bresolin S; Porcù E; Frasson C; Indraccolo S; Basso G; Accordi B
    Blood; 2017 Dec; 130(25):2750-2761. PubMed ID: 29101238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NUP214-ABL1-mediated cell proliferation in T-cell acute lymphoblastic leukemia is dependent on the LCK kinase and various interacting proteins.
    De Keersmaecker K; Porcu M; Cox L; Girardi T; Vandepoel R; de Beeck JO; Gielen O; Mentens N; Bennett KL; Hantschel O
    Haematologica; 2014 Jan; 99(1):85-93. PubMed ID: 23872305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical pharmacokinetic and pharmacodynamic evaluation of dasatinib and ponatinib for the treatment of T-cell acute lymphoblastic leukemia.
    Yoshimura S; Panetta JC; Hu J; Li L; Gocho Y; Du G; Umezawa A; Karol SE; Pui CH; Mullighan CG; Konopleva M; Stock W; Teachey DT; Jain N; Yang JJ
    Leukemia; 2023 Jun; 37(6):1194-1203. PubMed ID: 37076694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation.
    Schade AE; Schieven GL; Townsend R; Jankowska AM; Susulic V; Zhang R; Szpurka H; Maciejewski JP
    Blood; 2008 Feb; 111(3):1366-77. PubMed ID: 17962511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia.
    Gocho Y; Liu J; Hu J; Yang W; Dharia NV; Zhang J; Shi H; Du G; John A; Lin TN; Hunt J; Huang X; Ju B; Rowland L; Shi L; Maxwell D; Smart B; Crews KR; Yang W; Hagiwara K; Zhang Y; Roberts K; Wang H; Jabbour E; Stock W; Eisfelder B; Paietta E; Newman S; Roti G; Litzow M; Easton J; Zhang J; Peng J; Chi H; Pounds S; Relling MV; Inaba H; Zhu X; Kornblau S; Pui CH; Konopleva M; Teachey D; Mullighan CG; Stegmaier K; Evans WE; Yu J; Yang JJ
    Nat Cancer; 2021 Mar; 2(3):284-299. PubMed ID: 34151288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells.
    Mestermann K; Giavridis T; Weber J; Rydzek J; Frenz S; Nerreter T; Mades A; Sadelain M; Einsele H; Hudecek M
    Sci Transl Med; 2019 Jul; 11(499):. PubMed ID: 31270272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia.
    Saygin C; Giordano G; Shimamoto K; Eisfelder B; Thomas-Toth A; Venkataraman G; Ananthanarayanan V; Vincent TL; DuVall A; Patel AA; Chen Y; Tan F; Anthony SP; Chen Y; Shen Y; Odenike O; Teachey DT; Kee BL; LaBelle J; Stock W
    Clin Cancer Res; 2023 Aug; 29(16):3151-3161. PubMed ID: 37363966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TCR-induced T cell activation leads to simultaneous phosphorylation at Y505 and Y394 of p56(lck) residues.
    Nyakeriga AM; Garg H; Joshi A
    Cytometry A; 2012 Sep; 81(9):797-805. PubMed ID: 22674786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyrosine 192 within the SH2 domain of the Src-protein tyrosine kinase p56
    Kästle M; Merten C; Hartig R; Kaehne T; Liaunardy-Jopeace A; Woessner NM; Schamel WW; James J; Minguet S; Simeoni L; Schraven B
    Cell Commun Signal; 2020 Nov; 18(1):183. PubMed ID: 33225946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.